Center for Pharmaceutical Biotechnology, University of Colorado Denver Health Sciences Center, Aurora, Colorado, USA.
J Pharm Sci. 2012 Aug;101(8):2702-19. doi: 10.1002/jps.23215. Epub 2012 Jun 6.
Controlling aggregation in protein therapeutics is a significant challenge. In this study, the aggregation behavior of albinterferon-α(2b) , a genetic fusion protein combining human serum albumin and α-interferon, was examined as a function of solution conditions. The stability was monitored during agitation and during storage at elevated temperature, where the extent of aggregation was determined using size-exclusion chromatography. The osmotic second virial coefficient and the free energy of unfolding were measured for each sample. This study demonstrates that both increasing conformational stability and maximizing colloidal stability help to maintain the physical stability of albinterferon-α(2b).
控制蛋白质治疗药物的聚集是一项重大挑战。在这项研究中,研究了人血清白蛋白和 α-干扰素融合蛋白 albinterferon-α(2b)的聚集行为随溶液条件的变化。在搅拌过程中和在高温下储存过程中监测稳定性,使用排阻色谱法测定聚集程度。测量了每个样品的渗透压第二维里系数和展开自由能。本研究表明,增加构象稳定性和最大限度地提高胶体稳定性有助于维持 albinterferon-α(2b)的物理稳定性。